Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma, Lupin...

    Sun Pharma, Lupin Recall Over 41,500 Drug Bottles In US

    Written by savita thakur thakur Published On 2016-09-29T12:35:26+05:30  |  Updated On 29 Sept 2016 12:35 PM IST
    Sun Pharma, Lupin Recall Over 41,500 Drug Bottles In US

    New Delhi : Domestic drug majors Sun Pharmaceutical Industries and Lupin are recalling 41,737 bottles of three drugs used for various ailments such as high blood pressure, depression and anxiety in the US.


    Sun Pharmaceutical Industries Inc is recalling 12,109 bottles of Carvediol tablets USP used for treatment of high blood pressure, according to the latest Enforcement Report of the US Food and Drug Administration (USFDA).


    The recall covers tablets in strengths of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg in the US in a ongoing voluntary nationwide recall, it added.


    The recall is due to "failed impurities/degradation specifications," the report said.


    The tablets were manufactured at Hungary based ALKALOIDA Chemical Company Zrt, which is a subsidiary of Sun Pharma.


    On the other hand, Lupin is recalling 3,192 bottles of Escitalopram and 26,436 bottles of Lisinopril tablets.


    While Escitalopram tablets are used for treatment of depression and anxiety, Lisinopril tablets are indicated for treating hypertension.


    The recall of Escitalopram tablets USP in the strength of 20 mg is on account of "Labeling: incorrect or missing lot and/or expiration date," the report said.


    The product was made for Lupin Pharmaceuticals Baltimore by Lupin at its Goa facility.


    As per the report, Lupin's recall of Lisinopril tablets for strengths of 30 mg and 40 mg is on account of GMP deviations as the finished products were manufactured using active pharmaceutical ingredients, whose intermediates failed specifications.


    The product was made at Lupin's Pithampur facility, it added.


    All the three voluntary ongoing recalls are class III, the enforcement report said.


    As per the USFDA, class III recall is initiated in a situation "in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."

    anxietyCarvedioldepressionEscitalopramGMPhigh blood pressureLisinoprilLupinSun PharmaUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok